Apr 10, 2022

20 years in, Genentech persists and perseveres in Alzheimer’s with gantenerumab

Posted by in categories: biotech/medical, health, neuroscience

Genentech’s Gregory Rippon, M.D., associates a few different phrases with the challenging nature of Alzheimer’s disease drug development: “cautious optimism,” “steady progress,” “an exercise in per | Genentech has been working on gantenerumab for 20 years, and, while it’s tempting to try to rush the clinical process, the Roche unit is slowly but surely following the evidence.

Comments are closed.